针对冠状病毒的抑制剂的最新发现和开发。
Recent discovery and development of inhibitors targeting coronaviruses.
机构信息
PharmaCenter Bonn, Pharmaceutical Institute, Department of Pharmaceutical and Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany.
Department of Chemistry, Sri Krishna College of Engineering and Technology, Coimbatore, Tamil Nadu, India.
出版信息
Drug Discov Today. 2020 Apr;25(4):668-688. doi: 10.1016/j.drudis.2020.01.015. Epub 2020 Jan 30.
Human coronaviruses (CoVs) are enveloped viruses with a positive-sense single-stranded RNA genome. Currently, six human CoVs have been reported including human coronavirus 229E (HCoV-229E), OC43 (HCoV-OC43), NL63 (HCoV-NL63), HKU1 (HCoV-HKU1), severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV), and MiddleEast respiratory syndrome (MERS) coronavirus (MERS-CoV). They cause moderate to severe respiratory and intestinal infections in humans. In this review, we focus on recent advances in the research and development of small-molecule anti-human coronavirus therapies targeting different stages of the CoV life cycle.
人类冠状病毒（CoVs）是具有正链单链 RNA 基因组的包膜病毒。目前已报道六种人类 CoVs，包括人冠状病毒 229E（HCoV-229E）、OC43（HCoV-OC43）、NL63（HCoV-NL63）、HKU1（HCoV-HKU1）、严重急性呼吸综合征（SARS）冠状病毒（SARS-CoV）和中东呼吸综合征（MERS）冠状病毒（MERS-CoV）。它们会导致人类中、重度呼吸道和肠道感染。在本综述中，我们重点关注针对冠状病毒生命周期不同阶段的小分子抗人类冠状病毒疗法的最新研究进展。
Zotero 插件